RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. (12th June 2019) - Wang, M.; Ramchandren, R.; Chen, R.; Karlin, L.; Chong, G.; Jurczak, W.; Wu, K.; Bishton, M.; Collins, G.; Eliadis, P.; Peyrade, F.; Freise, K.; et al.